Register

Radiation Oncology

Pancreatic Cancer   

Questions discussed in this category

Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?
Would you ever consider this approach for an initially polymetastatic patient?
2 Answers available
For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?
1 Answer available
What are your top takeaways from ASCO GI 2023?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...
8 Answers available
In light of the recently published Alliance A021501 trial, what is your approach to incorporating SBRT for the treatment of borderline resectable pancreatic cancer?
A021501 trial: mFOLFIRINOX vs mFOLFIRINOX with hypofractionated radiation (Katz et al., PMID 35834226)
1 Answer available
How would you treat single celiac focus of adenocarcinoma of unknown primary?
Would you consider SBRT as post-chemo consolidation for a patient with a single unresectable focus of metastatic adenocarcinoma at the celiac axis?&nb...
1 Answer available


Papers discussed in this category

JAMA,
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
J Clin Oncol, 2022 Jan 27
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
BMC Cancer, 2021 Mar 23
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Int J Radiat Oncol Biol Phys, 2019 Jan 23
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
The New England journal of medicine, 2013-10-31
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
N. Engl. J. Med.,
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Lancet, 2021 Jun 05
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Eur J Cancer, 2018 Aug 24
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
JAMA Oncol, 2022 Apr 1
Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
Int J Radiat Oncol Biol Phys, 2023 Mar 01
Alleviating morbidity from locally advanced breast cancer using a practical and short radiotherapy regime: Results of the HYPORT palliative studies.
Seminars in radiation oncology, 2002 Jul
Intensity-modulated radiation therapy: the inverse, the converse, and the perverse.
Int J Radiat Oncol Biol Phys, 2022 Jul 04
A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer.
Lancet (London, England), 2023 Dec 14
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

Related Topics in Radiation Oncology

Copyright © 2024 theMednet
All Rights Reserved.